期刊文献+

ALT——端粒延长替代机制 被引量:10

ALT——Alternative lengthening of telomere
在线阅读 下载PDF
导出
摘要 端粒长度和结构的稳定与肿瘤及衰老的发生密切相关,端粒维持机制是细胞增殖的必要条件,端粒维持机制的激活是肿瘤细胞演化过程中的一个重要环节。这种端粒维持机制可能是通过重新激活端粒酶,使细胞快速增殖。在端粒酶失活或不足的情况下,也存在着一种或多种维持和增加端粒长度的机制,统称为端粒延长替代机制(Alterative lengthening of telomere,ALT)。其特点包括:具有不均一的端粒长度,存在与ALT相关的PML小体(APBs)以及同源重组增加。ALT细胞内存在的ALT相关蛋白及异常活跃的同源重组为ALT机制的激活和维持提供了可能。文章综述了ALT的特征性表型、与端粒酶的相关性及其可能的发生机制。对ALT机制的深入研究将有利于阐明衰老与肿瘤之间的辩证关系。 The maintenance of the length and normal structure of telomeres is highly related to the development of senescence and tumorigenesis. The mechanisms of maintaining telomere are essential for cell growth and the reactivation of these mechanisms is an important step in tumor progression. The mechanism of telomere maintenance might be the reactivation of telomerase. In the case of telomerase deficiency, the mechanisms for maintaining the lengths of telomeres are referred to as alternative lengthening of telomere (ALT). The characteristics of the ALT ceils include great heterogeneity of telomere size in individual cells, ALT-associated PML (promyelocytic leukemia) bodies, and evident homologous recombination. The ALT-related proteins and elevated homologous recombination found in ALT cells provide a possible mechanism for the alternative lengthening of telomere. The study of ALT provides a new view of crosstalk between senescence and tumorigenesis.
出处 《遗传》 CAS CSCD 北大核心 2009年第12期1185-1191,共7页 Hereditas(Beijing)
基金 国家自然科学基金项目(编号:30771194 30960152) 云南省科技计划项目(编号:2008C043M) 教育部新世纪优秀人才项目资助
关键词 端粒延长替代机制 与ALT相关的PML小体 同源重组 端粒蛋白复合体 端粒 ALT APBs homologous recombination shelterin telomere
  • 相关文献

参考文献34

  • 1Laud PR, Multani AS, Bailey SM, Wu L, Ma J, Kingsley C, Lebel M, Pathak S, DePinho RA, Chang S. Elevated telomere-telomere recombination in WRN-deficient, telomere dysfunctional cells promotes escape from senescence and engagement of the ALT pathway. Genes Dev, 2005, 19(21): 2560-2570.
  • 2Chang S, Khoo CM, Naylor ML, Maser RS, DePinho RA. Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. Genes Dev, 2003, 17(1): 88-100.
  • 3Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J, 1995, 14(17): 4240-4248.
  • 4Henderson S, Allsopp R, Spector D, Wang SS, Harley C. In situ analysis of changes in telomere size during replicative aging and cell transformation. J Cell Biol, 1996, 134(1): 1-12.
  • 5Henson JD, Neumann AA, Yeager TR, Reddel RR. Alternative lengthening of telomeres in mammalian cells. Oneogene, 2002, 21(4): 598-610.
  • 6Jegou T, Chung I, Heuvelman G, Wachsmuth M, Gorisch SM, Greulich-Bode KM, Boukamp P, Lichter P, Rippe K. Dynamics of telomeres and promyelocytic leukemia nuclear bodies in a telomerase-negative human cell line. Mol Biol Cell, 2009, 20(7): 2070-2082.
  • 7Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR, Reddel RR. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res, 1999, 59(17): 4175-4179.
  • 8Potts PR, Yu H. The SMC5/6 complex maintains telomere length in ALT cancer cells through SUMOylation of telomere-binding proteins. Nat Struct Mol Biol, 2007, 14(7): 581-590.
  • 9Grobelny JV, Godwin AK, Broccoli D. ALT-associated PML bodies are present in viable cells and are enriched in cells in the G(2)/M phase of the cell cycle. J Cell Sci, 2000, 113(Pt 24): 4577-4585.
  • 10Jiang WQ, Zhong ZH, Henson JD, Neumann AA, Chang AC, Reddel RR. Suppression of alternative lengthening of telomeres by Sp100-mediated sequestration of the MREll/RAD50/NBS1 complex. Mol Cell Biol, 2005, 25(7): 2708-2721.

同被引文献97

  • 1崔亚竹.端粒酶在临床中的研究进展[J].卫生职业教育,2004,22(24):126-127. 被引量:2
  • 2曹娟,郑杰,吕秀宁.维生素C增强As_2O_3诱导宫颈癌HeLa细胞凋亡的研究[J].东南大学学报(医学版),2005,24(5):294-299. 被引量:3
  • 3余秉翔,朱捷,刘又宁,郑晓飞.端粒酶催化亚基脱氧核酶抑制A549/DDP耐药细胞生长的实验研究[J].中国肺癌杂志,2006,9(5):405-408. 被引量:5
  • 4张士侠,李心,尹家乐,陈莉莉,张洪泉.江苏地产白首乌C_(21)甾苷抗衰老作用研究[J].实用老年医学,2007,21(2):104-107. 被引量:11
  • 5Bryan TM, Englezou A, Dalla-Pozza L, et al. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med, 1997, 3: 1271-1274.
  • 6Lafferty-Whyte K, Cairney CJ, Will MB, et al. A gene expres- sion signature classifying telomerase and ALT immortalization re- veals an hTERT regulatory network and suggests a mesenchymal stem 6ell origin for ALT. Oncogene, 2009, 28 : 3765-3774.
  • 7Ford LP, Zou Y, Pongracz K, et al. Telomerase can inhibit the recombination-based pathway of telomere maintenance in human cells. J Biol Chem, 2001, 276: 32198-32203.
  • 8Chen W, Xiao BK, Liu JP, et al. Alternative lengthening of telomeres in hTERT-inhibited laryngeal cancer ceils. Cancer Sci, 2010,101 : 1769-1776.
  • 9Perrem K, Colgin LM, Neumann AA, et al. Coexistence of al- ternative lengthening of telomeres and telomerase in hTERT- transfected GM847 cells. Mol Cell Biol, 2001, 21: 3862- 3875.
  • 10Martinez P, Blasco MA. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat Rev Cancer, 2011,11: 161-176.

引证文献10

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部